依洛尤单抗在冠心病降脂治疗中的应用
The application of ilozumab in the treatment of coronary heart disease
ES评分 0
| DOI |
10.12208/j.ijcr.20240271 |
| 刊名 |
International Journal of Clinical Research
|
| 年，卷(期) |
2024, 8(7) |
| 作者 |
|
| 作者单位 |
山东省青岛西海岸新区人民医院 山东青岛 ;
|
| 摘要 |
讨论在冠心病降脂治疗中应用依洛尤单抗的临床效果。方法 选取本院收治的冠心病患者70例（研究时间2021年7月-2022年7月），根据分层随机抽样方法分组，对照组（n=35）采用他汀类药物治疗，治疗组（n=35）在使用他汀类药物基础上再应用依洛尤单抗进行治疗。比较两组患者用药后的血脂水平、心功能指标以及治疗期间出现的不良反应情况。结果 治疗组用药干预后的TC、TG、LDL-C水平比对照组低，且CO、SVC、LVEF水平高于对照组（P＜0.05）；治疗组用药治疗期间出现的不良反应发生率小于对照组（P＜0.05）。结论 依洛尤单抗药物在冠心病降脂治疗过程中具有积极药物效果，可以有效降低患者血脂水平，改善心功能状态，且安全性高，值得临床应用。
|
| Abstract |
Objective To discuss the clinical efficacy of using ilozumab in lipid-lowering treatment for coronary heart disease. Methods 70 patients with coronary heart disease admitted to our hospital (study period: July 2021 to July 2022) were selected and divided into two groups using a stratified random sampling method. The control group (n=35) received statin therapy, while the treatment group (n=35) received ilozumab in addition to statin therapy. Compare the blood lipid levels, cardiac function indicators, and adverse reactions during treatment between two groups of patients after medication. Results TC TG and LDL-C levels were lower than the control group, and CO The levels of SVC and LVEF were higher than those of the control group (P<0.05); The incidence of adverse reactions during medication treatment in the treatment group was lower than that in the control group (P<0.05). Conclusion Yiluoyumab has a positive drug effect in the lipid-lowering treatment of coronary heart disease, which can effectively reduce blood lipid levels in patients, improve cardiac function, and has high safety. It is worthy of clinical application.
|
| 关键词 |
冠心病；降脂治疗；依洛尤单抗；血脂水平
|
| KeyWord |
Coronary heart disease; Lipid-lowering therapy; Ilozumab; Blood lipid level
|
| 基金项目 |
|
| 页码 |
112-114 |
赵梅,周兴鹏,崔耀金*.
依洛尤单抗在冠心病降脂治疗中的应用 [J].
国际临床研究杂志.
2024; 8; (7).
112 - 114.